Pierre-Julien Viailly
Overview
Explore the profile of Pierre-Julien Viailly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pulcini S, Beaussire-Trouvay L, Marguet F, Viailly P, Langlois O, Alexandru C, et al.
J Neurooncol
. 2024 Nov;
171(3):619-628.
PMID: 39549128
Background: The incidence of glioblastoma in the elderly population is increasing as the worldwide population ages. The differential and poorer survival in the elderly population compared to younger patients is...
2.
Camus V, Viennot M, Viailly P, Drieux F, Veresezan E, Bobee V, et al.
Blood Adv
. 2024 Sep;
9(1):101-115.
PMID: 39293080
There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA...
3.
Bobee V, Viennot M, Rainville V, Veresezan L, Drieux F, Viailly P, et al.
Hemasphere
. 2024 Mar;
8(2):e50.
PMID: 38435425
Follicular lymphoma (FL) course is highly variable, making its clinical management challenging. In this incurable and recurring pathology, the interval between relapses tends to decrease while aggressiveness increases, sometimes resulting...
4.
Chabane K, Charlot C, Gugenheim D, Simonet T, Armisen D, Viailly P, et al.
Leukemia
. 2023 Dec;
38(2):420-423.
PMID: 38135759
High-throughput sequencing plays a pivotal role in hematological malignancy diagnostics, but interpreting missense mutations remains challenging. In this study, we used the newly available AlphaMissense database to assess the efficacy...
5.
Camus V, Viailly P, Drieux F, Veresezan E, Sesques P, Haioun C, et al.
Blood Adv
. 2023 Oct;
7(23):7331-7345.
PMID: 37862676
Primary mediastinal B-cell lymphoma (PMBL) is an uncommon entity of aggressive B-cell lymphoma with an unusually good prognosis, except for 10-15% of chemotherapy-refractory cases. To identify earlier these higher risk...
6.
Lan X, Ruminy P, Bohers E, Rainville V, Viennot M, Viailly P, et al.
Leuk Res
. 2022 Oct;
123:106952.
PMID: 36272389
The mutational status of the variable region of the immunoglobulin heavy chain gene (IGHV) is a very important biomarker for chronic lymphocytic leukemia (CLL) patients. However, the routine detection of...
7.
Thieblemont C, Chartier L, Duhrsen U, Vitolo U, Barrington S, Zaucha J, et al.
Blood Adv
. 2022 Aug;
6(23):5995-6004.
PMID: 36044385
Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial...
8.
Sater V, Viailly P, Lecroq T, Prieur-Gaston E, Bohers E, Viennot M, et al.
Methods Mol Biol
. 2022 Jun;
2493:235-245.
PMID: 35751818
The rapid transition from traditional sequencing methods to Next-Generation Sequencing (NGS) has allowed for a faster and more accurate detection of somatic variants (Single-Nucleotide Variant (SNV) and Copy Number Variation...
9.
Maitre E, Tomowiak C, Lebecque B, Bijou F, Benabed K, Naguib D, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454811
Hairy cell leukemia (cHCL) patients have, in most cases, a specific clinical and biological presentation with splenomegaly, anemia, leukopenia, neutropenia, monocytopenia and/or thrombocytopenia, identification of hairy cells that express CD103,...
10.
Camus V, Viennot M, Leveque E, Viailly P, Tonnelet D, Veresezan E, et al.
Leuk Lymphoma
. 2022 Jan;
63(4):834-844.
PMID: 35075971
Few data exist concerning circulating tumor DNA (ctDNA) relevance in primary mediastinal B-cell lymphoma (PMBL). To explore this topic, we applied a 9-gene next-generation sequencing pipeline to samples from forty-four...